ETHYL LAUROYL ARGINATE HCL CAS NO.60372-77-2

Ethyl lauroyl arginate is synthesized by esterifying arginine with ethanol, followed by reacting the ester

with lauroyl chloride. The resultant ethyl lauroyl arginate is recovered as hydrochloride salt and is a

white, solid product which is filtered off and dried. Ethyl lauroyl arginate is a white powder and its solubility in water at 20ºC is greater than 247 g/kg. It is stable

for more than 2 years at room temperature when protected in a closed container. This substance is

intended to be used as preservative for its anti-microbial activity

Functional uses: 

    Ethyl lauroyl arginate HCl is used as preservative. Ethyl lauroyl arginate HCl which is a cationic surfactant has a wide spectrum    of activity against Gram positive and negative bacteria, yeasts and moulds. It acts on cell membranesand the cytoplasm, and inhibits the growth of populations but in no case is celllysis observed under the conditions studied. It can be used in a wide range of foods.

COA

Wuhan BJM Pharm Inc. was found in 2013, located in Hubei Province, where has long history, rich culture, convenient traffic, beautiful environment and preferential policy.

We have two factories in Dezhou , Shandong and Xianning, Hubei. The factory covers an area of 48,000 square meters with the building area of 26,000 square meters. We are specialized in the manufacture of pharmaceutical intermediates and cosmetic additives with good inspection equipments and innovative R & D capability.

In 2006, We established Lingxian Microworld Chemical New Material Co,.Ltd.

In 2008, We passed ISO quality system certificate

In 2013, We established Wuhan Benjamin Pharmaceutical Chemical Co.,Ltd , and obtain self-operation Import & Export right, mainly responsible for domestic and foreign business. At the same time, we set up R&D lab in Wuhan,Hubei province, can undertake various custom synthesis of intermediates and APIs.

In 2016,  obtain a registered trademark “ BJM ”.

In 2017, we applied for the invention patent of TRIS, and in 2018, we applied for the invention patent of ERDOSTAN intermediate（DL-HOMO）. At present, we have6 patents passed the preliminary examination, and 4 patents are under examination and approval.

In 2019, we purchased a R&D and office building with a total area of 2500 square meters, as our headquarters in Wuhan.

In 2020, we registered BJM Pharm Yunmeng Co., Ltd,  and the new production base settled in Geputan chemical park with  a total area of 50000 square meters.

We are specialized in the R&D ,production and sales of Erdosteine ,Pirfenidone, Telmisartan, Letrozole , Sitagliptin phosphate, Dapagliflozin , Tris , IPTG and related intermediates.

We stick to the principle as: people-oriented, customer first, Hope to establish a win-win business relationship with all friends.